ES521362A0 - Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina. - Google Patents

Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina.

Info

Publication number
ES521362A0
ES521362A0 ES521362A ES521362A ES521362A0 ES 521362 A0 ES521362 A0 ES 521362A0 ES 521362 A ES521362 A ES 521362A ES 521362 A ES521362 A ES 521362A ES 521362 A0 ES521362 A0 ES 521362A0
Authority
ES
Spain
Prior art keywords
lankacidine
cyclodextrin
antibiotics
inclusion
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES521362A
Other languages
English (en)
Other versions
ES8405032A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ES8405032A1 publication Critical patent/ES8405032A1/es
Publication of ES521362A0 publication Critical patent/ES521362A0/es
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES521362A 1982-04-12 1983-04-11 Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina. Granted ES521362A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57061343A JPS58177949A (ja) 1982-04-12 1982-04-12 ランカシジン群抗生物質包接化合物

Publications (2)

Publication Number Publication Date
ES8405032A1 ES8405032A1 (es) 1984-05-16
ES521362A0 true ES521362A0 (es) 1984-05-16

Family

ID=13168385

Family Applications (1)

Application Number Title Priority Date Filing Date
ES521362A Granted ES521362A0 (es) 1982-04-12 1983-04-11 Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina.

Country Status (8)

Country Link
US (1) US4497803A (es)
EP (1) EP0091782B1 (es)
JP (1) JPS58177949A (es)
CA (1) CA1216581A (es)
DE (1) DE3372577D1 (es)
DK (1) DK158883A (es)
ES (1) ES521362A0 (es)
ZA (1) ZA832471B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
HU196230B (en) * 1983-12-29 1988-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing water-soluble forms of polyene antibiotics and pharmaceutics comprising such active ingredient and plant protective with antifungal effect
US4616008A (en) * 1984-05-02 1986-10-07 Takeda Chemical Industries, Ltd. Antibacterial solid composition for oral administration
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
JPS61207380A (ja) * 1985-03-11 1986-09-13 Taiyo Yakuhin Kogyo Kk モベンゾキサミンの経口製剤
US4914206A (en) * 1985-10-06 1990-04-03 Takeda Chemical Industries, Ltd. Lankacidin derivatives and production thereof
ES2058057T3 (es) * 1985-12-05 1994-11-01 Takeda Chemical Industries Ltd Derivados de lancacidina y su produccion.
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AT400674B (de) * 1991-07-24 1996-02-26 Biochemie Gmbh Pharmazeutische pleuromutilin-zubereitung
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
WO1998029108A2 (en) * 1996-12-30 1998-07-09 The Johns Hopkins University School Of Medicine Compositions and methods for restoring a normal pattern of imprinting to cells
EP1332756A3 (en) * 1996-12-30 2003-12-10 The Johns Hopkins University School Of Medicine Compositions and methods for restoring a normal pattern of imprinting to cells
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
PT1608344E (pt) * 2003-03-28 2010-09-02 Ares Trading Sa Formulações orais de cladribina
MXPA05010330A (es) * 2003-03-28 2006-05-31 Ivax Corp Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa.
UA81305C2 (en) 2003-07-02 2007-12-25 Ares Trading Sa Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture
CA2553573A1 (en) 2004-01-29 2005-08-11 Eisai R & D Management Co., Ltd. Method for stabilizing macrolide compound
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US8845627B2 (en) * 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
JPS4810442B1 (es) * 1968-10-26 1973-04-03
US3869443A (en) * 1971-02-25 1975-03-04 Sterling Drug Inc N,N{40 -Heptamethylenebis(4-trifluoromethoxybenzamide)-{62 -cyclodextrin inclusion complex
JPS5738569B2 (es) * 1974-03-27 1982-08-16
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
JPS5724312A (en) * 1980-07-18 1982-02-08 Taisho Pharmaceut Co Ltd Polyether antibiotic clathrate compound
US4407795A (en) * 1981-07-16 1983-10-04 American Cyanamid Company Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use

Also Published As

Publication number Publication date
CA1216581A (en) 1987-01-13
US4497803A (en) 1985-02-05
ES8405032A1 (es) 1984-05-16
EP0091782A2 (en) 1983-10-19
DE3372577D1 (en) 1987-08-27
JPS58177949A (ja) 1983-10-18
EP0091782A3 (en) 1984-09-26
ZA832471B (en) 1983-12-28
DK158883A (da) 1983-10-13
DK158883D0 (da) 1983-04-11
JPH0336827B2 (es) 1991-06-03
EP0091782B1 (en) 1987-07-22

Similar Documents

Publication Publication Date Title
ES521362A0 (es) Un procedimiento para preparar compuestos de inclusion de antibioticos del grupo de la lankacidina con ciclodextrina.
ES508085A0 (es) Un procedimiento para la preparacion del complejo antibiotico a-4696.
ES528627A0 (es) Un procedimiento para la preparacion de pirazolo-y piridazo-pirazolinas,-piridazinas y-diazepinas.
ES494435A0 (es) Un procedimiento para la preparacion de nuevos antibioticos de milbecina.
ES523315A0 (es) Un procedimiento para la preparacion de antibioticos de carbapenem.
ES519735A0 (es) Un procedimiento para preparar peptidos sinteticos del tipo de las calcitoninas.
ES523064A0 (es) Procedimiento para preparar azetidinas.
ES521318A0 (es) Un procedimiento para la preparacion de compuestos de bencimidazol.
ES520364A0 (es) Un procedimiento para preparar compuestos de cefem.
ES522120A0 (es) Un procedimiento para la preparacion de 4-aril-4-piperidincarbinoles.
ES521278A0 (es) Un procedimiento para preparar un derivado del complejo activador de plasminogeno humano-estreptoquinasa.
ES520812A0 (es) Procedimiento para la preparacion de 3-azolil-1,2-diaril-1-halogeno-1-propenos.
ES520866A0 (es) Un procedimiento para la preparacion del complejo a41030.
ES516929A0 (es) Un procedimiento para la preparacion de etilenglicol.
ES500038A0 (es) Un procedimiento para la preparacion de un derivado de 3-o- desmetilsannamicina c o del antibiotico ax-127b-1.
ES507034A0 (es) Un procedimiento para la preparacion de derivados tetrasubs-tituidos del benceno.
ES523136A0 (es) Un procedimiento para la preparacion de un compuesto.
ES510117A0 (es) Un procedimiento para la preparacion de antibioticos b-lactamicos.
ES496391A0 (es) Un procedimiento para la preparacion de antibioticos de b-lactama.
ES521714A0 (es) Procedimiento para la obtencion de antibiotico de p-lactama.
ES523582A0 (es) Procedimiento para la fabricacion de un hilo fantasia.
IT8321573A0 (it) Procedimento per la preparazione del meta-clorobenzotrifluoruro.
ES522278A0 (es) Un procedimiento para preparacion de una quinalozina.
ES523682A0 (es) Un procedimiento para preparar compuestos de cefalosporina.
ES523441A0 (es) Un procedimiento para la produccion de compuestos poliprenilicos.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19971201